(News Bulletin 247) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday the results of a phase III study showing that experimental therapy combining macitentan 10 mg and tadalafil 40 mg in a single tablet led to a ‘significant improvement ‘ Pulmonary hemodynamics (i.e., blood flow in the pulmonary blood vessels) compared to monotherapies with macitentan and tadalafil in patients with pulmonary arterial hypertension (PAH) functional class (FC) II or III of the Organization World Health Organization (WHO).

J&J recalls that PAH is a rare, progressive and potentially fatal disease that affects the blood vessels. It is characterized by the constriction of the small pulmonary arteries and an increase in blood pressure which eventually leads to heart failure.

The study results were presented at the American College of Cardiology’s 72nd Annual Scientific Session and Exposition at the World Heart Federation’s World Congress of Cardiology.

Copyright (c) 2023 News Bulletin 247. All rights reserved.